New Cholesterol Drug May Lessen Popularity of Statin Tied to Lipitor Lawsuit Filings, Research Suggests

Published on April 3, 2014 by Sandy Liebhard

Text-Size:A A A+


A new cholesterol medication from Amgen Inc. may eventually replace a statin tied to Type 2 diabetes in a number of Lipitor lawsuit filings, reports

According to an article on April 1st, the new drug, evolocumab may lower LDL (bad cholesterol) levels in the blood by mimicking the effects of a genetic mutation that lowers blood fat levels. Several clinical trials and a string of recent studies presented at the 63rd Annual Scientific Session of the American College of Cardiology (ACC) found patients taking the medication saw their LDL levels lowered by at least 66 percent.

According to one study, which recently appeared in the New England Journal of Medicine, individuals who received monthly injections of evolocumab for a year saw their bad cholesterol lowered by 57 percent. Those already taking a drug allegedly associated with Lipitor diabetes side effects, experienced a 47 percent lowered reduction rate of LDL levels.

Research published March 29th in the Journal of American College of Cardiology further underlined the effectiveness of evolocumab, in findings that patients taking Lipitor for three months saw their LDL levels reduced by 57 percent.

And patients continued to see positive results after that. “At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in patients with a range of cardiovascular risks,” investigators said at the ACC meeting.

Lipitor Lawsuit Litigation Now Includes 270 Claims

News of this research may prove noteworthy to individuals who have come forward to file Lipitor lawsuits. According to court documents in April 2014, at least 270 cases had been filed in the U.S. District Court, District of South Carolina by plaintiffs who claimed to have developed the disease. Individuals in these cases allege that Pfizer failed to warn about side effects associated with the cholesterol-lowering statin prior to marketing the medication, and may have concealed vital safety information from the public. Many of these cases follow revelations in JAMA: Internal Medicine that showed an increased risk for diabetes in post-menopausal women taking Lipitor.

In March 2012, the U.S. Food and Drug Administration (FDA) ordered statin manufacturers including Pfizer to adjust their drug labels to include a possible association with Type 2 diabetes. Lipitor lawsuit claimants argue that the new labeling continues to remain insufficient in warning patients of its potential for side effects.

Filing a Lipitor Lawsuit

Did you develop Type 2 diabetes after taking Lipitor? Contact the attorneys at Bernstein Liebhard LLP, who are actively filing cases over the medication. Call us now for more information about Lipitor lawsuits at .